Yes, there are several FDA-approved medications that can slow the progression of Alzheimer’s disease, and the options have expanded significantly in recent years. The treatments fall into three categories: drugs that boost brain communication to manage symptoms, a drug that protects brain cells from damage, and newer antibody therapies that target the underlying disease itself. Which medications apply depends largely on how far the disease has progressed.
Newer Antibody Treatments That Target the Disease
The most significant development in Alzheimer’s treatment is a class of drugs that go beyond managing symptoms and actually slow the biological progression of the disease. The FDA has approved two antibody therapies, lecanemab (Leqembi) and donanemab (Kisunla), for people with mild cognitive impairment or mild dementia due to Alzheimer’s. These drugs work by clearing amyloid plaques, the sticky protein clumps that build up in the brain and drive Alzheimer’s damage.
In clinical trials, donanemab reduced the risk of progressing to the next stage of the disease by about 39% compared to placebo, and participants gained roughly 4 to 7 months before their symptoms worsened over the 18-month study period. That may not sound dramatic, but in early-stage Alzheimer’s, where every month of preserved independence matters, those months carry real weight for patients and families.
These treatments are given as intravenous infusions every four weeks. Donanemab infusions take about 30 minutes each session. The first three doses start at a lower amount before increasing, and treatment may actually stop once brain scans show amyloid plaques have dropped to minimal levels. That’s a meaningful distinction from older Alzheimer’s drugs, which are taken indefinitely.
Who Qualifies
Not everyone with Alzheimer’s is eligible. These antibody treatments are approved only for early-stage disease, meaning mild cognitive impairment or mild dementia. Before starting treatment, your doctor must confirm the presence of amyloid plaques in your brain, typically through a PET scan or spinal fluid test. If amyloid isn’t detected, the drugs won’t help because the target they’re designed to clear isn’t there.
Side Effects to Know About
The most notable risk with these antibody therapies is a set of brain changes visible on MRI, known collectively as ARIA. These include brain swelling (or fluid accumulation) and small areas of bleeding. Across anti-amyloid drugs studied in trials, brain swelling showed up on scans in 13% to 35% of patients, though only 3% to 9% had symptoms they could feel, like headache or confusion. Small brain bleeds appeared in 14% to 27% of participants. People who carry two copies of the APOE4 gene, a known Alzheimer’s risk gene, face substantially higher rates. Regular MRI monitoring is part of the treatment protocol to catch these changes early.
Cost and Insurance
Medicare Part B covers FDA-approved antibody treatments for Alzheimer’s, but with conditions. Your provider must enroll you in a qualifying study or registry that tracks how well the drugs work in real-world use. You’ll also need a confirmed diagnosis of mild cognitive impairment or mild Alzheimer’s dementia with evidence of amyloid plaques. If you meet the criteria, you pay 20% of the Medicare-approved amount after your Part B deductible. Brain scans and tests required before and during treatment can add to out-of-pocket costs. If you don’t meet Part B criteria, some Part D prescription plans may offer coverage as an alternative.
Medications That Manage Symptoms
Before the antibody drugs arrived, the standard approach was a group of medications called cholinesterase inhibitors. These don’t change the course of the disease itself, but they help the brain work more efficiently with what it has left. In Alzheimer’s, brain cells lose their ability to communicate because levels of a key chemical messenger drop as neurons die. Cholinesterase inhibitors block the enzyme that breaks down this messenger, keeping more of it available to relay signals between brain cells. The three options in this class are donepezil, galantamine, and rivastigmine.
These drugs are typically prescribed for mild to moderate Alzheimer’s. They can improve or stabilize memory, attention, and the ability to carry out daily tasks for a period of months to years, though they don’t stop the underlying brain degeneration. They’re taken as daily pills or, in rivastigmine’s case, a skin patch.
A Different Drug for Later Stages
Memantine works through an entirely different mechanism and is approved for moderate to severe Alzheimer’s. While cholinesterase inhibitors boost a fading chemical signal, memantine protects brain cells from a different kind of damage. In Alzheimer’s, another brain chemical called glutamate becomes overactive and essentially overwhelms neurons, causing them to deteriorate faster. Memantine blocks this toxic overactivation while still allowing normal brain signaling to continue. The result is neuroprotective: it shields remaining brain cells rather than boosting their output.
Because memantine and cholinesterase inhibitors work through completely separate pathways, they’re often prescribed together. A network meta-analysis found that combining memantine with donepezil produced better outcomes for cognition, daily functioning, behavioral symptoms, and overall clinical assessment than either drug alone. The combination outperformed each individual medication across all four dimensions studied. The tradeoff was that patients found the combination slightly less tolerable, likely due to the added side effects of taking two medications.
How These Treatments Work Together
The current landscape of Alzheimer’s medication is layered. In early stages, a person might receive one of the new antibody therapies to slow disease progression at its root, alongside a cholinesterase inhibitor to sharpen day-to-day cognitive function. As the disease advances into moderate and severe stages, memantine enters the picture, often combined with an existing cholinesterase inhibitor. No single drug does everything, but used strategically across the course of the disease, the available medications address both the symptoms a person experiences and, increasingly, the biological process driving them.
The antibody treatments represent a genuine shift. For the first time, there are drugs that measurably delay how quickly Alzheimer’s worsens, not just mask the symptoms. They’re limited to early-stage disease and come with real risks and logistical demands, but for people caught early enough, they offer something that didn’t exist a few years ago: time.